Back

Antithrombotic therapy in patients with atrial fibrillation undergoing PCI – Represented in NEJM by the PIONEER-AF PCI trial and the RE-DUAL PCI trial

26 August 2018 (08:52 - 09:15)
Organised by:
Congress Presentation Part of: Highlights from the New England Journal of Medicine: Editors’ Choice Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Christopher Paul Cannon

Brigham and Women's Hospital, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
Antithrombotic therapy in stable cardiovascular disease - Represented in NEJM by the COMPASS trial and the PEGASUS-TIMI 54 trial
Doctor J. Eikelboom (Hamilton, CA)
Slides Video
Presentation thumbnail
Fractional Flow Reserve-Guided PCI – represented in NEJM by the FAME, FAME-2, Compare-Acute, IFR-SWEDEHEART, and DEFINE-FLAIR trials
Professor E. Barbato (Rome, IT)
Slides Video
Presentation thumbnail
PFO closure for cryptogenic stroke – Represented in NEJM by the CLOSURE I, PC, REDUCE, CLOSE, and RESPECT trials
Professor L. Sondergaard (Copenhagen, DK)
Slides Video

Access the full session

Session thumbnail
Highlights from the New England Journal of Medicine: Editors’ Choice

The Event

Event poster

ESC Congress 2018

26 August 2018 08:52 CET
You may be interested in
thumbnail
Congress Presentation
Meta-analysis of clinical trials comparing triple versus dual antithrombotic therapy on risk reduction of stent thrombosis after percutaneous coronary intervention in atrial fibrillation patients
27 August 2021
thumbnail
Congress Presentation
Atrial fibrillation in patients with cancer: what’s new and how to implement
20 June 2026
thumbnail
Congress Presentation
Association between personalized evidence-based anticoagulation therapy and outcomes at 1-year follow-up in patients with atrial fibrillation: an analysis from the Atrial Fibrillation Registry
29 June 2021
thumbnail
Congress Presentation
Atrial fibrillation in patients with acute coronary syndrome under clopidogrel versus ticagrelor.
13 March 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources